



Neuren (NEU) – ASX Announcement

21 August 2026

Neuren H1 2026 Financial Results Webinar on 26 August 2026

H1 2026 Financial Results Webinar | Wednesday, 26 August 2026 at 11.00 AM AEST

You are invited to register using this link:

https://us06web.zoom.us/webinar/register/WN_c13nFh-NRsSq1BMcsc65Jg

Participants may submit questions at registration or during the session

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) management will host an investor webinar on Wednesday, 26 August 2026 at 11:00 AM Australian Eastern Standard Time to discuss Neuren's H1 2026 financial results. Registration for the webinar may be completed via the link above.

About Neuren

Neuren Pharmaceuticals is developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options. Neuren's therapies target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides.

DAYBUE® (trofinetide) oral solution is approved by the US Food and Drug Administration (FDA), Health Canada and the Ministry of Health in Israel and DAYBUE STIX (trofinetide) powder is approved by the FDA for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's investigative drug candidate, NNZ-2591 (ercanetide), is in clinical development as an oral solution treatment for multiple neurodevelopmental disorders, including Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Each of these programs has been granted "orphan drug" designation in the United States and the European Union as well as Fast Track and Rare Pediatric Disease designations from the FDA. Neuren is also developing NNZ-2591 for the treatment of hypoxic ischemic encephalopathy (HIE), a serious condition caused by brain injury before or shortly after birth.

Currently, Neuren is conducting a Phase 3, randomized, double-blind, placebo-controlled clinical trial ("Koala") evaluating the safety and efficacy of NNZ-2591 in children aged 3 to 12 years with Phelan-McDermid syndrome and a 52-week open-label extension study.



Investor contact:

Jon Pilcher, CEO & Managing Director

+61 438 422 271

investorrelations@neurenpharma.com

Media Contact:

Monsoon Communications

Rudi Michelson

rudim@monsoon.com.au

Investor Hub



ASX Listing Rules information

This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC 3123

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.